Description
GLYCOMART-BF — Triple-Action Inhaler Therapy for Better Breathing
GLYCOMART-BF combines Glycopyrrolate 9 mcg, Formoterol Fumarate 4.8 mcg, and Budesonide 160 mcg in a single metered-dose inhaler, bringing together a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid. Glycopyrrolate and Formoterol work together to relax airway muscles and sustain bronchodilation, while Budesonide addresses the underlying airway inflammation that drives exacerbations. This triple-action approach reflects the direction respiratory therapy has moved toward for patients who need more than dual bronchodilation alone, making GLYCOMART-BF a clinically relevant option for pulmonologists and physicians managing chronic respiratory conditions, and a meaningful addition to any franchise partner’s respiratory range.
Precision That Matters in Inhaler Manufacturing
Lxir Medilabs is an ISO and WHO-GMP certified pharmaceutical company headquartered in Panchkula, Haryana with manufacturing carried out at our Baddi, Himachal Pradesh facility. A triple-combination metered-dose inhaler demands exact dose uniformity across every actuation, since inconsistent delivery directly affects a patient’s breathing control. GLYCOMART-BF is manufactured under strict quality protocols to ensure this dose-to-dose reliability, giving franchise partners a dependable product to introduce to pulmonologists and general physicians building long-term respiratory care relationships. For a PCD pharma franchise company in India, this precision is what separates a credible respiratory range from a basic one.
Product Highlights for Franchise Partners
- Composition: Glycopyrrolate 9 mcg + Formoterol Fumarate 4.8 mcg + Budesonide 160 mcg
- Dosage Form: Inhaler
- Pack Size: 120 Metered Doses
- Pack Type: Inhaler for convenient, portable use
- Key Benefit: Triple-action control for better breathing
- Suited For: Distributors and medical representatives expanding their respiratory product range
Franchise partners looking to add a triple-therapy inhaler to their respiratory portfolio can explore this and other formulations through our PCD pharma franchise division, with complete promotional support.
Disclaimer: This is a prescription inhaler and should be used strictly under the supervision of a registered medical practitioner.
